Reference number : GC-2017-Q3-00543, amendment number : , agreement type : G, recipient legal name : Rose, David (University of Waterloo), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Plants can be used as an efficient and cost-effective means of producing therapeutic proteins, and have several_x000D_
advantages over recombinant cell culture approaches. These include high yields, cheap growing costs,_x000D_
regulatory advantages, and the ability to produce proteins with minimal infrastructure._x000D_
One challenge, no matter what method is used, is to make the products resemble human proteins, so that_x000D_
they do not stimulate an immune response in the recipient. Most therapeutic proteins are coated with_x000D_
complexes of sugar molecules (polysaccharides or glycans). In order to avoid rejection, these have to mimic_x000D_
human glycan structures._x000D_
The goal of this project is to study the plant mechanisms that make the glycans on proteins. Many of these_x000D_
have been identified by sequencing the plant genome. However, the details of how they function, and how they_x000D_
might be modified to make human-like glycans, are the subject of this study._x000D_
The partner company, PlantForm, is developing technologies for making therapeutic proteins in plants. The_x000D_
results of this project will provide a foundation for advances in these technologies that facilitate the masking of_x000D_
the products within a human-like glycan shell, and making them tolerable to administer to patients., program purpose french : Plants can be used as an efficient and cost-effective means of producing therapeutic proteins, and have several_x000D_
advantages over recombinant cell culture approaches. These include high yields, cheap growing costs,_x000D_
regulatory advantages, and the ability to produce proteins with minimal infrastructure._x000D_
One challenge, no matter what method is used, is to make the products resemble human proteins, so that_x000D_
they do not stimulate an immune response in the recipient. Most therapeutic proteins are coated with_x000D_
complexes of sugar molecules (polysaccharides or glycans). In order to avoid rejection, these have to mimic_x000D_
human glycan structures._x000D_
The goal of this project is to study the plant mechanisms that make the glycans on proteins. Many of these_x000D_
have been identified by sequencing the plant genome. However, the details of how they function, and how they_x000D_
might be modified to make human-like glycans, are the subject of this study._x000D_
The partner company, PlantForm, is developing technologies for making therapeutic proteins in plants. The_x000D_
results of this project will provide a foundation for advances in these technologies that facilitate the masking of_x000D_
the products within a human-like glycan shell, and making them tolerable to administer to patients., agreement title english : N-glycosylation enzymes of Nicotiana benthamiana: Identification and structure/function analysis, agreement title french : N-glycosylation enzymes of Nicotiana benthamiana: Identification and structure/function analysis, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-11-08, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada